BG107447A - Приложение на щамове parapoxvirus ovis при органни фибрози - Google Patents
Приложение на щамове parapoxvirus ovis при органни фибрози Download PDFInfo
- Publication number
- BG107447A BG107447A BG107447A BG10744703A BG107447A BG 107447 A BG107447 A BG 107447A BG 107447 A BG107447 A BG 107447A BG 10744703 A BG10744703 A BG 10744703A BG 107447 A BG107447 A BG 107447A
- Authority
- BG
- Bulgaria
- Prior art keywords
- fibrosis
- manufacture
- liver
- preventive
- cells
- Prior art date
Links
- 241000700639 Parapoxvirus Species 0.000 title claims abstract description 32
- 206010016654 Fibrosis Diseases 0.000 title claims description 25
- 230000004761 fibrosis Effects 0.000 title claims description 21
- 241000283898 Ovis Species 0.000 title 1
- 210000000056 organ Anatomy 0.000 claims abstract description 13
- 241000282414 Homo sapiens Species 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 17
- 230000009471 action Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 230000003449 preventive effect Effects 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000006978 adaptation Effects 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 230000002828 effect on organs or tissue Effects 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 25
- 210000004185 liver Anatomy 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 21
- 102000008186 Collagen Human genes 0.000 abstract description 13
- 108010035532 Collagen Proteins 0.000 abstract description 13
- 229920001436 collagen Polymers 0.000 abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 10
- 230000008021 deposition Effects 0.000 abstract description 3
- 201000003883 Cystic fibrosis Diseases 0.000 abstract description 2
- 206010019799 Hepatitis viral Diseases 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 201000001862 viral hepatitis Diseases 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 39
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 19
- 239000002775 capsule Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000007912 intraperitoneal administration Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000008215 water for injection Substances 0.000 description 10
- 210000004051 gastric juice Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 5
- 210000003995 blood forming stem cell Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003352 fibrogenic effect Effects 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 238000013223 sprague-dawley female rat Methods 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 101150065641 Gpdh1 gene Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000000208 hepatic perisinusoidal cell Anatomy 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002036 metaphylactic effect Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229960004250 polygeline Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- BXSDMMPOQRECKB-UHFFFAOYSA-N sodium;chloro-(4-methylphenyl)sulfonylazanide;hydrate Chemical compound O.[Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 BXSDMMPOQRECKB-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10033581 | 2000-07-11 | ||
| DE10122233A DE10122233A1 (de) | 2000-07-11 | 2001-05-08 | Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen |
| PCT/EP2001/007978 WO2002004019A2 (de) | 2000-07-11 | 2001-07-11 | Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107447A true BG107447A (bg) | 2003-09-30 |
Family
ID=26006334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107447A BG107447A (bg) | 2000-07-11 | 2003-01-08 | Приложение на щамове parapoxvirus ovis при органни фибрози |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6632647B2 (lt) |
| EP (1) | EP1303302B1 (lt) |
| JP (1) | JP5106736B2 (lt) |
| CN (1) | CN1452496B (lt) |
| AR (1) | AR028800A1 (lt) |
| AU (2) | AU8582701A (lt) |
| BG (1) | BG107447A (lt) |
| CA (1) | CA2415399C (lt) |
| CZ (1) | CZ200372A3 (lt) |
| DK (1) | DK200300014A (lt) |
| EE (1) | EE200300019A (lt) |
| FI (1) | FI20030038A7 (lt) |
| GB (1) | GB2383752B (lt) |
| HK (1) | HK1054330B (lt) |
| HR (1) | HRP20030097A2 (lt) |
| HU (1) | HU227668B1 (lt) |
| IL (1) | IL153826A0 (lt) |
| LT (1) | LT5064B (lt) |
| LU (1) | LU90996B1 (lt) |
| LV (1) | LV12991B (lt) |
| MA (1) | MA25765A1 (lt) |
| MX (1) | MXPA03000278A (lt) |
| NO (1) | NO20030081D0 (lt) |
| NZ (1) | NZ523535A (lt) |
| PL (1) | PL360839A1 (lt) |
| RU (1) | RU2003104522A (lt) |
| SE (1) | SE0300033L (lt) |
| SI (1) | SI21171A (lt) |
| SK (1) | SK382003A3 (lt) |
| WO (1) | WO2002004019A2 (lt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
| US6752995B2 (en) | 2002-04-15 | 2004-06-22 | Board Of Regents, The University Of Texas System | Nucleic acid and polypeptide sequences useful as adjuvants |
| EP1499355A4 (en) | 2001-12-07 | 2005-10-05 | Bayer Pharmaceuticals Corp | USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES |
| EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2012045473A1 (en) * | 2010-10-07 | 2012-04-12 | Technische Universität München | Viruses for the treatment of fibrosis |
| EA201891848A1 (ru) | 2016-02-16 | 2019-02-28 | Осака Юниверсити | Фармацевтическая композиция для применения в лечении фиброза |
| TW201919675A (zh) * | 2017-09-07 | 2019-06-01 | 德商艾庫瑞斯公司 | 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
| US4360510A (en) * | 1979-11-30 | 1982-11-23 | Proctor Julian W | Method for screening anti-tumor agents of the reticulo-endothelial stimulant class |
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| DE3504940C2 (de) | 1984-02-17 | 1997-11-06 | Bayer Ag | Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel |
| DE3816139A1 (de) * | 1987-10-17 | 1989-04-27 | Bayer Ag | Verfahren zur herstellung von paramunitaetsinducern |
| DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ATE203678T1 (de) * | 1996-04-15 | 2001-08-15 | Anton Prof Dr Med Vet Dr Mayr | Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln |
| DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
| IL139593A (en) * | 2000-11-09 | 2010-12-30 | Biogem Optical Ltd | Method for the detection of viable microorganisms |
-
2001
- 2001-07-11 CZ CZ200372A patent/CZ200372A3/cs unknown
- 2001-07-11 GB GB0302629A patent/GB2383752B/en not_active Expired - Lifetime
- 2001-07-11 HK HK03106614.0A patent/HK1054330B/zh not_active IP Right Cessation
- 2001-07-11 CA CA2415399A patent/CA2415399C/en not_active Expired - Lifetime
- 2001-07-11 WO PCT/EP2001/007978 patent/WO2002004019A2/de not_active Ceased
- 2001-07-11 SK SK38-2003A patent/SK382003A3/sk not_active Application Discontinuation
- 2001-07-11 LU LU90996A patent/LU90996B1/en active
- 2001-07-11 FI FI20030038A patent/FI20030038A7/fi not_active IP Right Cessation
- 2001-07-11 EP EP01965110A patent/EP1303302B1/de not_active Expired - Lifetime
- 2001-07-11 HR HR20030097A patent/HRP20030097A2/xx not_active Application Discontinuation
- 2001-07-11 AR ARP010103291A patent/AR028800A1/es not_active Application Discontinuation
- 2001-07-11 AU AU8582701A patent/AU8582701A/xx active Pending
- 2001-07-11 NZ NZ52353501A patent/NZ523535A/xx unknown
- 2001-07-11 RU RU2003104522/15A patent/RU2003104522A/ru not_active Application Discontinuation
- 2001-07-11 IL IL15382601A patent/IL153826A0/xx active IP Right Grant
- 2001-07-11 EE EEP200300019A patent/EE200300019A/xx unknown
- 2001-07-11 SI SI200120047A patent/SI21171A/sl not_active IP Right Cessation
- 2001-07-11 HU HU0303830A patent/HU227668B1/hu not_active IP Right Cessation
- 2001-07-11 US US09/903,005 patent/US6632647B2/en not_active Expired - Lifetime
- 2001-07-11 AU AU2001285827A patent/AU2001285827B2/en not_active Expired
- 2001-07-11 CN CN018151272A patent/CN1452496B/zh not_active Expired - Lifetime
- 2001-07-11 PL PL36083901A patent/PL360839A1/xx not_active Application Discontinuation
- 2001-07-11 JP JP2002508473A patent/JP5106736B2/ja not_active Expired - Lifetime
- 2001-07-11 MX MXPA03000278A patent/MXPA03000278A/es active IP Right Grant
-
2003
- 2003-01-08 NO NO20030081A patent/NO20030081D0/no not_active Application Discontinuation
- 2003-01-08 BG BG107447A patent/BG107447A/bg unknown
- 2003-01-10 SE SE0300033A patent/SE0300033L/xx not_active Application Discontinuation
- 2003-01-10 DK DK200300014A patent/DK200300014A/da not_active Application Discontinuation
- 2003-01-10 MA MA26995A patent/MA25765A1/fr unknown
- 2003-02-03 LT LT2003008A patent/LT5064B/lt not_active IP Right Cessation
- 2003-02-11 LV LVP-03-13A patent/LV12991B/lv unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0149677B1 (ko) | 안정화된 생 백신 | |
| CN102858959B (zh) | 溶瘤弹状病毒 | |
| CN102803477B (zh) | 新城疫病毒的新克隆、其制备及其在癌症医学治疗中的应用 | |
| BG107447A (bg) | Приложение на щамове parapoxvirus ovis при органни фибрози | |
| JP5950964B2 (ja) | 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用 | |
| CN114377127A (zh) | 一种三联卵黄抗体制剂及其制备方法和应用 | |
| TWI807609B (zh) | 乳酸菌用於提升對腸病毒71型之抵抗力之用途 | |
| KR102353119B1 (ko) | 시아노박테리아 추출물, 이의 제조 방법 및 그 용도 | |
| JP7639136B2 (ja) | 呼吸器ウイルス感染症の処置又は予防のためのスーパーオキシドジスムターゼ活性を有するポリペプチド及び細胞外小胞の使用 | |
| CN111329859B (zh) | 叶绿素铜钠盐在制备用于抗肠道病毒的药物中的应用 | |
| HK1060050A (en) | Use of strains of the parapox ovis virus against organ fibrosis | |
| TWI803229B (zh) | 一種化合物tsyi-zac用於抑制登革熱病毒感染及其醫藥治療用途 | |
| CN118526483A (zh) | 一种天然植物来源的联苯多酚化合物在制备治疗疱疹性疾病的药物中的应用 | |
| WO2022000167A1 (zh) | 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用 | |
| CN115475196A (zh) | 腹安颗粒浸膏在制备用于治疗手足口病的药物中的用途 | |
| CN117018034A (zh) | 胎盘源细胞因子在治疗和预防疱疹病毒感染及其相关疾病的应用 | |
| CN116987171A (zh) | 一种用于防治疱疹病毒感染的胎盘源细胞因子制备方法及其制剂的应用 | |
| Lozitsky | Anti-Infectious Actions of Proteolysis Inhibitor e-Aminocaproic Acid (ε-ACA) | |
| Kriek | IOUOnivIers~ ityIF~ ree~ St~ ate~~~~~~~~~ 34300002088221 Universiteit Vrystaat The Oncolytic Properties of Two Newcastle Disease Virus Strains. | |
| Vivo | Functional Antagonism of Chemokine |